Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan

• Ataru Igarashi,
• Hideyuki Nomura,
• Kazufumi Dohmen,
• Nobuhiko Higashi,
• Kazuhiro Takahashi,
• Akira Kawano,
• Takeaki Satoh,
• Makoto Nakamuta,
• Toshimasa Koyanagi,
• Masaki Kato,
• Shinji Shimoda,
• Eiji Kajiwara

Affiliations

Ataru Igarashi

1 Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan

Hideyuki Nomura

4 The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan

Kazufumi Dohmen

5 Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan

Nobuhiko Higashi

6 Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan

Kazuhiro Takahashi

7 Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan

Akira Kawano

8 Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

Takeaki Satoh

10 Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan

Makoto Nakamuta

11 Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan

Toshimasa Koyanagi

12 Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan

Masaki Kato

13 Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Shinji Shimoda

14 Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Eiji Kajiwara

15 Kajiwara Clinic, Kitakyushu, Japan